Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Dow
Moodys
Medtronic
Boehringer Ingelheim

Last Updated: March 29, 2023

Spain: These 61 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

DrugPatentWatch® Estimated Loss of Exclusivity Dates in Spain

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Spain: These 61 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024" DrugPatentWatch.com thinkBiotech, 2023 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can QUTENZA (capsaicin) generic drug versions launch?

Generic name: capsaicin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 14, 2023
Generic Entry Controlled by: Spain Patent 2,288,222

QUTENZA is a drug marketed by Averitas. There are seven patents protecting this drug.

This drug has eighty-five patent family members in twenty-nine countries. There has been litigation on patents covering QUTENZA

See drug price trends for QUTENZA.

The generic ingredient in QUTENZA is capsaicin. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the capsaicin profile page.

When can CONTRAVE (bupropion hydrochloride; naltrexone hydrochloride) generic drug versions launch?

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 29, 2023
Generic Entry Controlled by: Spain Patent 2,303,085

CONTRAVE is a drug marketed by Nalpropion. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixty patent family members in forty-three countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

When can CONTRAVE (bupropion hydrochloride; naltrexone hydrochloride) generic drug versions launch?

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 29, 2023
Generic Entry Controlled by: Spain Patent 2,639,579

CONTRAVE is a drug marketed by Nalpropion. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixty patent family members in forty-three countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

When can CONTRAVE (bupropion hydrochloride; naltrexone hydrochloride) generic drug versions launch?

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 29, 2023
Generic Entry Controlled by: Spain Patent 2,760,464

CONTRAVE is a drug marketed by Nalpropion. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixty patent family members in forty-three countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

When can PREVYMIS (letermovir) generic drug versions launch?

Generic name: letermovir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 02, 2023
Generic Entry Controlled by: Spain Patent 2,284,007

PREVYMIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.

This drug has eighty-five patent family members in forty-five countries.

See drug price trends for PREVYMIS.

The generic ingredient in PREVYMIS is letermovir. One supplier is listed for this generic product. Additional details are available on the letermovir profile page.

When can NOURIANZ (istradefylline) generic drug versions launch?

Generic name: istradefylline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 09, 2023
Generic Entry Controlled by: Spain Patent 2,384,685

NOURIANZ is a drug marketed by Kyowa Kirin. There are four patents protecting this drug.

This drug has sixty-three patent family members in eighteen countries.

See drug price trends for NOURIANZ.

The generic ingredient in NOURIANZ is istradefylline. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the istradefylline profile page.

When can OMONTYS (peginesatide acetate) generic drug versions launch?

Generic name: peginesatide acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 12, 2023
Generic Entry Controlled by: Spain Patent 2,323,465

OMONTYS is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug.

This drug has one hundred and fourteen patent family members in thirty-four countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

When can MAYZENT (siponimod fumaric acid) generic drug versions launch?

Generic name: siponimod fumaric acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: Spain Patent 2,379,169

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

When can MAYZENT (siponimod fumaric acid) generic drug versions launch?

Generic name: siponimod fumaric acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: Spain Patent 2,467,160

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

When can MAYZENT (siponimod fumaric acid) generic drug versions launch?

Generic name: siponimod fumaric acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: Spain Patent 2,558,761

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

When can MAYZENT (siponimod fumaric acid) generic drug versions launch?

Generic name: siponimod fumaric acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: Spain Patent 2,593,463

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

When can ILEVRO (nepafenac) generic drug versions launch?

Generic name: nepafenac
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2023
Generic Entry Controlled by: Spain Patent 2,410,505

Drug Price Trends for ILEVRO
ILEVRO is a drug marketed by Novartis. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in twenty-six countries. There has been litigation on patents covering ILEVRO

See drug price trends for ILEVRO.

The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the nepafenac profile page.

When can ILEVRO (nepafenac) generic drug versions launch?

Generic name: nepafenac
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2023
Generic Entry Controlled by: Spain Patent 2,415,738

Drug Price Trends for ILEVRO
ILEVRO is a drug marketed by Novartis. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in twenty-six countries. There has been litigation on patents covering ILEVRO

See drug price trends for ILEVRO.

The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the nepafenac profile page.

When can ILEVRO (nepafenac) generic drug versions launch?

Generic name: nepafenac
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2023
Generic Entry Controlled by: Spain Patent 2,570,856

Drug Price Trends for ILEVRO
ILEVRO is a drug marketed by Novartis. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in twenty-six countries. There has been litigation on patents covering ILEVRO

See drug price trends for ILEVRO.

The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the nepafenac profile page.

When can JANUMET (metformin hydrochloride; sitagliptin phosphate) generic drug versions launch?

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Spain Patent 2,291,907

Drug Price Trends for JANUMET
JANUMET is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JANUMET

See drug price trends for JANUMET.

The generic ingredient in JANUMET is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

When can JANUMET XR (metformin hydrochloride; sitagliptin phosphate) generic drug versions launch?

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Spain Patent 2,291,907

Drug Price Trends for JANUMET XR
JANUMET XR is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUMET XR

See drug price trends for JANUMET XR.

The generic ingredient in JANUMET XR is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

When can JANUVIA (sitagliptin phosphate) generic drug versions launch?

Generic name: sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Spain Patent 2,291,907

Drug Price Trends for JANUVIA
JANUVIA is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and one Paragraph IV challenge. Twelve tentatively approved generics are ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUVIA

See drug price trends for JANUVIA.

The generic ingredient in JANUVIA is sitagliptin phosphate. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the sitagliptin phosphate profile page.

When can JUVISYNC (simvastatin; sitagliptin phosphate) generic drug versions launch?

Generic name: simvastatin; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Spain Patent 2,291,907

JUVISYNC is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JUVISYNC

The generic ingredient in JUVISYNC is simvastatin; sitagliptin phosphate. There are forty drug master file entries for this API. Additional details are available on the simvastatin; sitagliptin phosphate profile page.

When can ORIAHNN (COPACKAGED) (elagolix sodium,estradiol,norethindrone acetate; elagolix sodium) generic drug versions launch?

Generic name: elagolix sodium,estradiol,norethindrone acetate; elagolix sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Spain Patent 2,314,448

ORIAHNN (COPACKAGED) is a drug marketed by Abbvie Inc. There are five patents protecting this drug.

This drug has thirty-eight patent family members in twenty-three countries. There has been litigation on patents covering ORIAHNN (COPACKAGED)

The generic ingredient in ORIAHNN (COPACKAGED) is elagolix sodium,estradiol,norethindrone acetate; elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium,estradiol,norethindrone acetate; elagolix sodium profile page.

When can ORILISSA (elagolix sodium) generic drug versions launch?

Generic name: elagolix sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Spain Patent 2,314,448

Drug Price Trends for ORILISSA
ORILISSA is a drug marketed by Abbvie Inc. There are six patents protecting this drug.

This drug has forty-three patent family members in twenty-four countries. There has been litigation on patents covering ORILISSA

See drug price trends for ORILISSA.

The generic ingredient in ORILISSA is elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 04, 2023
Generic Entry Controlled by: Spain Patent 2,389,840

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Allergan. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cariprazine hydrochloride profile page.

When can RYZODEG 70/30 (insulin aspart; insulin degludec) generic drug versions launch?

Generic name: insulin aspart; insulin degludec
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Spain Patent 2,402,592

RYZODEG 70/30 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering RYZODEG 70/30

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.

When can RYZODEG 70/30 (insulin aspart; insulin degludec) generic drug versions launch?

Generic name: insulin aspart; insulin degludec
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Spain Patent 2,472,421

RYZODEG 70/30 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering RYZODEG 70/30

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.

When can TRESIBA (insulin degludec) generic drug versions launch?

Generic name: insulin degludec
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Spain Patent 2,402,592

Drug Price Trends for TRESIBA
TRESIBA is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering TRESIBA

See drug price trends for TRESIBA.

The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec profile page.

When can TRESIBA (insulin degludec) generic drug versions launch?

Generic name: insulin degludec
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Spain Patent 2,472,421

Drug Price Trends for TRESIBA
TRESIBA is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering TRESIBA

See drug price trends for TRESIBA.

The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec profile page.

When can XULTOPHY 100/3.6 (insulin degludec; liraglutide) generic drug versions launch?

Generic name: insulin degludec; liraglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Spain Patent 2,402,592

XULTOPHY 100/3.6 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering XULTOPHY 100/3.6

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.

When can XULTOPHY 100/3.6 (insulin degludec; liraglutide) generic drug versions launch?

Generic name: insulin degludec; liraglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Spain Patent 2,472,421

XULTOPHY 100/3.6 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering XULTOPHY 100/3.6

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.

When can HUMALOG KWIKPEN (insulin lispro recombinant) generic drug versions launch?

Generic name: insulin lispro recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Spain Patent 2,721,548

HUMALOG KWIKPEN is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMALOG KWIKPEN

See drug price trends for HUMALOG KWIKPEN.

The generic ingredient in HUMALOG KWIKPEN is insulin lispro recombinant. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin lispro recombinant profile page.

When can HUMALOG MIX 50/50 KWIKPEN (insulin lispro protamine recombinant; insulin lispro recombinant) generic drug versions launch?

Generic name: insulin lispro protamine recombinant; insulin lispro recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Spain Patent 2,721,548

HUMALOG MIX 50/50 KWIKPEN is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMALOG MIX 50/50 KWIKPEN

The generic ingredient in HUMALOG MIX 50/50 KWIKPEN is insulin lispro protamine recombinant; insulin lispro recombinant. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin lispro protamine recombinant; insulin lispro recombinant profile page.

When can HUMALOG MIX 75/25 KWIKPEN (insulin lispro protamine recombinant; insulin lispro recombinant) generic drug versions launch?

Generic name: insulin lispro protamine recombinant; insulin lispro recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Spain Patent 2,721,548

HUMALOG MIX 75/25 KWIKPEN is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMALOG MIX 75/25 KWIKPEN

The generic ingredient in HUMALOG MIX 75/25 KWIKPEN is insulin lispro protamine recombinant; insulin lispro recombinant. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin lispro protamine recombinant; insulin lispro recombinant profile page.

When can HUMULIN 70/30 (insulin recombinant human; insulin susp isophane recombinant human) generic drug versions launch?

Generic name: insulin recombinant human; insulin susp isophane recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Spain Patent 2,721,548

HUMULIN 70/30 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMULIN 70/30

The generic ingredient in HUMULIN 70/30 is insulin recombinant human; insulin susp isophane recombinant human. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin recombinant human; insulin susp isophane recombinant human profile page.

When can HUMULIN N (insulin susp isophane recombinant human) generic drug versions launch?

Generic name: insulin susp isophane recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Spain Patent 2,721,548

Drug Price Trends for HUMULIN N
HUMULIN N is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMULIN N

See drug price trends for HUMULIN N.

The generic ingredient in HUMULIN N is insulin susp isophane recombinant human. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin susp isophane recombinant human profile page.

When can HUMULIN R (insulin human) generic drug versions launch?

Generic name: insulin human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Spain Patent 2,721,548

Drug Price Trends for HUMULIN R
HUMULIN R is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering HUMULIN R

See drug price trends for HUMULIN R.

The generic ingredient in HUMULIN R is insulin human. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin human profile page.

When can PRADAXA (dabigatran etexilate mesylate) generic drug versions launch?

Generic name: dabigatran etexilate mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: Spain Patent 2,326,654

Drug Price Trends for PRADAXA
PRADAXA is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug and two Paragraph IV challenges. Ten tentatively approved generics are ready to enter the market.

This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA

See drug price trends for PRADAXA.

The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.

When can PRADAXA (dabigatran etexilate mesylate) generic drug versions launch?

Generic name: dabigatran etexilate mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: Spain Patent 2,375,896

Drug Price Trends for PRADAXA
PRADAXA is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug and two Paragraph IV challenges. Ten tentatively approved generics are ready to enter the market.

This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA

See drug price trends for PRADAXA.

The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.

When can AIRDUO RESPICLICK (fluticasone propionate; salmeterol xinafoate) generic drug versions launch?

Generic name: fluticasone propionate; salmeterol xinafoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2023
Generic Entry Controlled by: Spain Patent 2,362,038

AIRDUO RESPICLICK is a drug marketed by Teva Pharm. There are sixteen patents protecting this drug.

This drug has four hundred and nineteen patent family members in thirty-seven countries. There has been litigation on patents covering AIRDUO RESPICLICK

The generic ingredient in AIRDUO RESPICLICK is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.

When can ALTABAX (retapamulin) generic drug versions launch?

Generic name: retapamulin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 03, 2023
Generic Entry Controlled by: Spain Patent 2,335,284

ALTABAX is a drug marketed by Almirall. There are two patents protecting this drug.

This drug has thirteen patent family members in six countries.

See drug price trends for ALTABAX.

The generic ingredient in ALTABAX is retapamulin. One supplier is listed for this generic product. Additional details are available on the retapamulin profile page.

When can ALVESCO (ciclesonide) generic drug versions launch?

Generic name: ciclesonide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 16, 2023
Generic Entry Controlled by: Spain Patent 2,452,691

Drug Price Trends for ALVESCO
ALVESCO is a drug marketed by Covis. There is one patent protecting this drug.

This drug has fourteen patent family members in twelve countries.

See drug price trends for ALVESCO.

The generic ingredient in ALVESCO is ciclesonide. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ciclesonide profile page.

When can OMNARIS (ciclesonide) generic drug versions launch?

Generic name: ciclesonide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 16, 2023
Generic Entry Controlled by: Spain Patent 2,452,691

Drug Price Trends for OMNARIS
OMNARIS is a drug marketed by Covis. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has fourteen patent family members in twelve countries.

See drug price trends for OMNARIS.

The generic ingredient in OMNARIS is ciclesonide. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ciclesonide profile page.

When can ZETONNA (ciclesonide) generic drug versions launch?

Generic name: ciclesonide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 16, 2023
Generic Entry Controlled by: Spain Patent 2,452,691

Drug Price Trends for ZETONNA
ZETONNA is a drug marketed by Covis. There is one patent protecting this drug.

This drug has fourteen patent family members in twelve countries.

See drug price trends for ZETONNA.

The generic ingredient in ZETONNA is ciclesonide. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ciclesonide profile page.

When can JEVTANA KIT (cabazitaxel) generic drug versions launch?

Generic name: cabazitaxel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 19, 2023
Generic Entry Controlled by: Spain Patent 2,403,149

JEVTANA KIT is a drug marketed by Sanofi Aventis Us. There are four patents protecting this drug. Two tentatively approved generics are ready to enter the market.

This drug has ninety-six patent family members in forty-six countries. There has been litigation on patents covering JEVTANA KIT

The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cabazitaxel profile page.

When can VIBATIV (telavancin hydrochloride) generic drug versions launch?

Generic name: telavancin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 22, 2023
Generic Entry Controlled by: Spain Patent 2,400,483

VIBATIV is a drug marketed by Cumberland Pharms. There are three patents protecting this drug.

This drug has one hundred and twenty-eight patent family members in thirty-five countries.

See drug price trends for VIBATIV.

The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this generic product. Additional details are available on the telavancin hydrochloride profile page.

When can VIBATIV (telavancin hydrochloride) generic drug versions launch?

Generic name: telavancin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 22, 2023
Generic Entry Controlled by: Spain Patent 2,477,268

VIBATIV is a drug marketed by Cumberland Pharms. There are three patents protecting this drug.

This drug has one hundred and twenty-eight patent family members in thirty-five countries.

See drug price trends for VIBATIV.

The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this generic product. Additional details are available on the telavancin hydrochloride profile page.

When can DUETACT (glimepiride; pioglitazone hydrochloride) generic drug versions launch?

Generic name: glimepiride; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 31, 2023
Generic Entry Controlled by: Spain Patent 2,556,244

DUETACT is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in thirty-one countries. There has been litigation on patents covering DUETACT

See drug price trends for DUETACT.

The generic ingredient in DUETACT is glimepiride; pioglitazone hydrochloride. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the glimepiride; pioglitazone hydrochloride profile page.

When can KUVAN (sapropterin dihydrochloride) generic drug versions launch?

Generic name: sapropterin dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2023
Generic Entry Controlled by: Spain Patent 2,596,827

KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and fourteen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN

See drug price trends for KUVAN.

The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.

When can KUVAN (sapropterin dihydrochloride) generic drug versions launch?

Generic name: sapropterin dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2023
Generic Entry Controlled by: Spain Patent 2,905,305

KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and fourteen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN

See drug price trends for KUVAN.

The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.

When can OSMOPREP (sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate) generic drug versions launch?

Generic name: sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 19, 2023
Generic Entry Controlled by: Spain Patent 2,584,866

OSMOPREP is a drug marketed by Salix Pharms. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-nine patent family members in eleven countries.

See drug price trends for OSMOPREP.

The generic ingredient in OSMOPREP is sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate. There are one thousand four hundred and seventy-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate profile page.

When can SAXENDA (liraglutide recombinant) generic drug versions launch?

Generic name: liraglutide recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Spain Patent 2,660,320

Drug Price Trends for SAXENDA
SAXENDA is a drug marketed by Novo. There are twenty-five patents protecting this drug.

This drug has two hundred and ninety-nine patent family members in thirty-two countries. There has been litigation on patents covering SAXENDA

See drug price trends for SAXENDA.

The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

When can SAXENDA (liraglutide recombinant) generic drug versions launch?

Generic name: liraglutide recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Spain Patent 2,727,854

Drug Price Trends for SAXENDA
SAXENDA is a drug marketed by Novo. There are twenty-five patents protecting this drug.

This drug has two hundred and ninety-nine patent family members in thirty-two countries. There has been litigation on patents covering SAXENDA

See drug price trends for SAXENDA.

The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

When can VICTOZA (liraglutide recombinant) generic drug versions launch?

Generic name: liraglutide recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Spain Patent 2,660,320

Drug Price Trends for VICTOZA
VICTOZA is a drug marketed by Novo Nordisk Inc. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-seven patent family members in thirty-two countries. There has been litigation on patents covering VICTOZA

See drug price trends for VICTOZA.

The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

When can VICTOZA (liraglutide recombinant) generic drug versions launch?

Generic name: liraglutide recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Spain Patent 2,727,854

Drug Price Trends for VICTOZA
VICTOZA is a drug marketed by Novo Nordisk Inc. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-seven patent family members in thirty-two countries. There has been litigation on patents covering VICTOZA

See drug price trends for VICTOZA.

The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

When can XARELTO (rivaroxaban) generic drug versions launch?

Generic name: rivaroxaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: Spain Patent 2,300,845

Drug Price Trends for XARELTO
XARELTO is a drug marketed by Janssen Pharms. There are five patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO

See drug price trends for XARELTO.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.

When can VYZULTA (latanoprostene bunod) generic drug versions launch?

Generic name: latanoprostene bunod
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: Spain Patent 2,566,800

Drug Price Trends for VYZULTA
VYZULTA is a drug marketed by Bausch And Lomb. There are four patents protecting this drug.

This drug has fifty-three patent family members in thirty-eight countries.

See drug price trends for VYZULTA.

The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.

When can VYZULTA (latanoprostene bunod) generic drug versions launch?

Generic name: latanoprostene bunod
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: Spain Patent 2,767,136

Drug Price Trends for VYZULTA
VYZULTA is a drug marketed by Bausch And Lomb. There are four patents protecting this drug.

This drug has fifty-three patent family members in thirty-eight countries.

See drug price trends for VYZULTA.

The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.

When can NAMZARIC (donepezil hydrochloride; memantine hydrochloride) generic drug versions launch?

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: Spain Patent 2,351,709

Drug Price Trends for NAMZARIC
NAMZARIC is a drug marketed by Allergan. There are twelve patents protecting this drug and three Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

When can NULIBRY (fosdenopterin hydrobromide) generic drug versions launch?

Generic name: fosdenopterin hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: Spain Patent 2,406,733

NULIBRY is a drug marketed by Sentynl Theraps Inc. There is one patent protecting this drug.

This drug has ten patent family members in ten countries.

The generic ingredient in NULIBRY is fosdenopterin hydrobromide. One supplier is listed for this generic product. Additional details are available on the fosdenopterin hydrobromide profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Spain Patent 2,431,388

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Spain Patent 2,439,736

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Spain Patent 2,501,594

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Spain Patent 2,619,608

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Spain Patent 2,631,362

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Spain Patent 2,778,846

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Spain Patent 2,791,303

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

When can EPANOVA (omega-3-carboxylic acids) generic drug versions launch?

Generic name: omega-3-carboxylic acids
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2024
Generic Entry Controlled by: Spain Patent 2,344,208

EPANOVA is a drug marketed by Astrazeneca. There are seven patents protecting this drug.

This drug has eighty-four patent family members in forty countries.

The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this API. Additional details are available on the omega-3-carboxylic acids profile page.

When can OSPHENA (ospemifene) generic drug versions launch?

Generic name: ospemifene
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 23, 2024
Generic Entry Controlled by: Spain Patent 2,364,970

Drug Price Trends for OSPHENA
OSPHENA is a drug marketed by Duchesnay. There are eight patents protecting this drug.

This drug has ninety-four patent family members in thirty-one countries. There has been litigation on patents covering OSPHENA

See drug price trends for OSPHENA.

The generic ingredient in OSPHENA is ospemifene. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ospemifene profile page.

When can JUXTAPID (lomitapide mesylate) generic drug versions launch?

Generic name: lomitapide mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 05, 2024
Generic Entry Controlled by: Spain Patent 2,399,721

JUXTAPID is a drug marketed by Amryt. There are eight patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries. There has been litigation on patents covering JUXTAPID

See drug price trends for JUXTAPID.

The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lomitapide mesylate profile page.

When can RUKOBIA (fostemsavir tromethamine) generic drug versions launch?

Generic name: fostemsavir tromethamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2024
Generic Entry Controlled by: Spain Patent 2,299,022

RUKOBIA is a drug marketed by Viiv Hlthcare. There are three patents protecting this drug.

This drug has thirty-nine patent family members in thirty countries.

See drug price trends for RUKOBIA.

The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this generic product. Additional details are available on the fostemsavir tromethamine profile page.

When can SYNJARDY (empagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Spain Patent 2,314,743

Drug Price Trends for SYNJARDY
SYNJARDY is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

When can SYNJARDY (empagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Spain Patent 2,387,881

Drug Price Trends for SYNJARDY
SYNJARDY is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

When can SYNJARDY XR (empagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Spain Patent 2,314,743

Drug Price Trends for SYNJARDY XR
SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

When can SYNJARDY XR (empagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Spain Patent 2,387,881

Drug Price Trends for SYNJARDY XR
SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

When can TEKTURNA (aliskiren hemifumarate) generic drug versions launch?

Generic name: aliskiren hemifumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: Spain Patent 2,747,941

Drug Price Trends for TEKTURNA
TEKTURNA is a drug marketed by Noden Pharma. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA

See drug price trends for TEKTURNA.

The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.

When can IMPLANON (etonogestrel) generic drug versions launch?

Generic name: etonogestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 19, 2024
Generic Entry Controlled by: Spain Patent 2,308,460

IMPLANON is a drug marketed by Organon. There is one patent protecting this drug.

This drug has thirty-two patent family members in twenty-six countries.

The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the etonogestrel profile page.

When can FORTEO (teriparatide recombinant human) generic drug versions launch?

Generic name: teriparatide recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Spain Patent 2,369,671

Drug Price Trends for FORTEO
FORTEO is a drug marketed by Lilly. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO

See drug price trends for FORTEO.

The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.

When can FORTEO (teriparatide recombinant human) generic drug versions launch?

Generic name: teriparatide recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Spain Patent 2,728,788

Drug Price Trends for FORTEO
FORTEO is a drug marketed by Lilly. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO

See drug price trends for FORTEO.

The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.

When can NATAZIA (dienogest; estradiol valerate) generic drug versions launch?

Generic name: dienogest; estradiol valerate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: Spain Patent 2,348,038

Drug Price Trends for NATAZIA
NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?

Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: Spain Patent 2,392,848

Drug Price Trends for INCRUSE ELLIPTA
INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries.

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?

Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: Spain Patent 2,600,405

Drug Price Trends for INCRUSE ELLIPTA
INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries.

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

When can VIZIMPRO (dacomitinib) generic drug versions launch?

Generic name: dacomitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Spain Patent 2,374,553

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety patent family members in forty-seven countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.

When can KYPROLIS (carfilzomib) generic drug versions launch?

Generic name: carfilzomib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Spain Patent 2,360,811

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

When can KYPROLIS (carfilzomib) generic drug versions launch?

Generic name: carfilzomib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Spain Patent 2,408,216

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

When can KYPROLIS (carfilzomib) generic drug versions launch?

Generic name: carfilzomib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Spain Patent 2,510,840

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

When can KYPROLIS (carfilzomib) generic drug versions launch?

Generic name: carfilzomib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Spain Patent 2,549,763

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

When can ARCAPTA NEOHALER (indacaterol maleate) generic drug versions launch?

Generic name: indacaterol maleate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Spain Patent 2,362,429

Drug Price Trends for ARCAPTA NEOHALER
ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has eighty-six patent family members in thirty-nine countries. There has been litigation on patents covering ARCAPTA NEOHALER

See drug price trends for ARCAPTA NEOHALER.

The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.

When can UTIBRON (glycopyrrolate ; indacaterol maleate) generic drug versions launch?

Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Spain Patent 2,362,429

UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON

See drug price trends for UTIBRON.

The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.

When can VITEKTA (elvitegravir) generic drug versions launch?

Generic name: elvitegravir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: Spain Patent 2,388,441

VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.

This drug has eighty-three patent family members in thirty-five countries. There has been litigation on patents covering VITEKTA

The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.

When can CAPRELSA (vandetanib) generic drug versions launch?

Generic name: vandetanib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: Spain Patent 2,330,025

CAPRELSA is a drug marketed by Genzyme Corp. There are three patents protecting this drug.

This drug has one hundred and forty-two patent family members in forty-three countries.

See drug price trends for CAPRELSA.

The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.

When can QNASL (beclomethasone dipropionate) generic drug versions launch?

Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: Spain Patent 2,339,574

Drug Price Trends for QNASL
QNASL is a drug marketed by Teva Branded Pharm. There are two patents protecting this drug.

This drug has fifty-two patent family members in thirty-two countries.

See drug price trends for QNASL.

The generic ingredient in QNASL is beclomethasone dipropionate. There are twenty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the beclomethasone dipropionate profile page.

When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?

Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Spain Patent 2,582,646

Drug Price Trends for KOMBIGLYZE XR
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering KOMBIGLYZE XR

See drug price trends for KOMBIGLYZE XR.

The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.

When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?

Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Spain Patent 2,593,582

Drug Price Trends for KOMBIGLYZE XR
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering KOMBIGLYZE XR

See drug price trends for KOMBIGLYZE XR.

The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.

When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?

Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Spain Patent 2,754,573

Drug Price Trends for KOMBIGLYZE XR
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering KOMBIGLYZE XR

See drug price trends for KOMBIGLYZE XR.

The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.

When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?

Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Spain Patent 2,582,646

Drug Price Trends for ONGLYZA
ONGLYZA is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering ONGLYZA

See drug price trends for ONGLYZA.

The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.

When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?

Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Spain Patent 2,593,582

Drug Price Trends for ONGLYZA
ONGLYZA is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering ONGLYZA

See drug price trends for ONGLYZA.

The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.

When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?

Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Spain Patent 2,754,573

Drug Price Trends for ONGLYZA
ONGLYZA is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering ONGLYZA

See drug price trends for ONGLYZA.

The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Mallinckrodt
Medtronic
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.